Discontinuing statin therapy safe, beneficial for patients with terminal illness
the ONA take:
According to a new study published in the JAMA Internal Medicine, researchers from 15 Palliative Care Research Cooperative Group member sites have found that it is acceptable for patients with cancer, heart disease, and other life-limiting illness to discontinue statin medications or begin discussions about discontinuing statin therapy.
For the study, researchers analyzed the outcomes of 381 patients with a mean age of 74 who had between 1 month and 1 year left to live. About half of participants had cancer. Researchers divided the participants into two groups and had one group continue to take statins while the other group did not.
Results showed that the 212 participants survived beyond 60 days of study initiation. Researchers found no significant difference between mortality rates of those who continued statin therapy (20.3%) versus those who discontinued statin therapy (23.8%).
In regard to cost savings, the study showed that the surviving participants would save $716 each over the trial period. The national annual savings in 2014 would have been $529 million for generic statins.
It is acceptable for patients with cancer and other life-limiting illness to discontinue statin medications.
Research published today in JAMA Internal Medicine shows that it's okay for patients with cancer, heart disease and other life-limiting illnesses to stop taking statin medications, or at least begin conversations about making that choice.
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors
- Directly Informing Patients of Breast Cancer Risk, Options Improves Follow-Up Screening
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- CTCs Promising as Biomarker to Identify Lung Cancer Recurrence
- Hypofractionated RT, Conventional RT Comparable in Intermediate-Risk Prostate Cancer
- Social Functioning Scores for Young Cancer Survivors Remain Lower Than Their Peers
- Mortality Rates Highest Among Youngest Oncology Patients, Particularly Minorities
- Survey Reveals Research Priorities for Cancer Patients, Oncology Nurses
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|